Phaseline

Targets › PLAU

PLAU (Urokinase-type plasminogen activator): drug programs, companies and trials

6 programs from 6 companies in 6 trials: 2 Phase 4, 2 Phase 3, 2 Phase 2; Neurology, Infectious disease, Cardiovascular; next expected readout Mar 2027.

Serine protease that cleaves the inactive precursor plasminogen at a specific Arg-Val peptide bond, converting it into active plasmin. Secreted as an inactive zymogen, it is recruited and activated at the cell surface through interaction with the urokinase plasminogen activator receptor (uPAR). (UniProt, P00749)

Open in Phaseline: the race on PLAU, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Second Affiliated Hospital of Nanchang UniversityUrokinase
Urokinase-type plasminogen activator exogenous protein
PLAUPhase 4Aneurysmal Subarachnoid HemorrhageJun 2027
University of North Carolina, Chapel Hilltissue plasminogen activator (tPA)
Fibrinolytic enzyme; serine protease that converts plasminogen to plasmin
PLAUPhase 4Pleural Infection BacterialSep 2028
First Affiliated Hospital Xi'an Jiaotong Universityrecombinant human prourokinase (rhPro-UK)
serine protease that activates plasminogen to plasmin, promoting fibrinolysis
PLAUPhase 3Acute Ischemic StrokeDec 2027
The First Affiliated Hospital of Anhui Medical UniversityRecombinant Human Prourokinase for Injection (rhPro-UK)
Serine protease that activates plasminogen to plasmin, promoting fibrin degradation and th
PLAUPhase 3Acute Ischemic StrokeJun 2029
Zhujiang HospitalNafamostat Mesilate
Serine protease inhibitor; anticoagulant
F2, F2R, PLAUPhase 2Continuous Renal Replacement Therapy (CRRT)Mar 2027
General Hospital of Shenyang Military Regionprourokinase
Thrombolytic agent; plasminogen activator that converts plasminogen to plasmin
PLAUPhase 2Acute Ischemic StrokeDec 2027

Conditions

Acute Ischemic Stroke (3) Pleural Infection Bacterial (1) Aneurysmal Subarachnoid Hemorrhage (1) Continuous Renal Replacement Therapy (CRRT) (1)

Modalities

protein or peptide (4), mixed (1), small molecule (1)

Companies

University of North Carolina, Chapel Hill (1) The First Affiliated Hospital of Anhui Medical University (1) General Hospital of Shenyang Military Region (1) First Affiliated Hospital Xi'an Jiaotong University (1) Second Affiliated Hospital of Nanchang University (1) Zhujiang Hospital (1)

Related targets

F2 (1) F2R (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.